Mydriacyl (Tropicamide)

Tropicamide works by selectively blocking muscarinic acetylcholine receptors, especially the M3 subtype, in the iris sphincter and ciliary muscles. This antagonism prevents parasympathetic stimulation, causing the sphincter muscle to relax and the pupil to enlarge, while also inhibiting the ciliary muscle’s ability to focus, resulting in cycloplegia. The pharmacologic action begins within minutes after ocular administration.

The exact dosing regimen for Mydriacyl is determined by the prescribing eye‑care professional based on the patient’s age, clinical indication, and response. Typically, a single drop is instilled in the conjunctival sac of each eye, and additional drops may be administered at prescribed intervals. Patients should follow the specific instructions provided by their clinician.

Safety data for tropicamide during pregnancy and lactation are limited, and the product is classified as a prescription‑only medication. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate the individual situation and consider alternative options if appropriate.

To order Mydriacyl from GNH India, submit an enquiry on the product page at gnhindia.com, specifying the required quantity and your organization’s details. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping arrangements (including any cold‑chain requirements), and assistance with import documentation.

The most common alternative to tropicamide is phenylephrine, an adrenergic agonist that also dilates the pupil but does not produce cycloplegia. Phenylephrine primarily acts on the dilator pupillae muscle, whereas tropicamide relaxes the sphincter muscle and paralyzes accommodation. Tropicamide generally has a faster onset and shorter duration, making it preferred for routine diagnostic dilation, while phenylephrine may be added for patients with poor response to tropicamide alone.

Mydriacyl eye drops should be stored at room temperature, below 25 °C, in the original sealed container. Protect the product from direct sunlight, excessive heat, and moisture. Do not freeze the solution, and discard any vial that appears cloudy, discolored, or has been opened beyond the recommended period after opening.

Mydriacyl is administered topically to the eye. The patient or caregiver should wash hands, tilt the head back, and gently pull down the lower eyelid to create a small pocket. One drop is placed into the conjunctival sac of the intended eye(s), avoiding contact between the tip of the bottle and the ocular surface. The eye can be closed gently for a few seconds to aid absorption.

The most serious risks associated with Mydriacyl include acute angle‑closure glaucoma, which can cause sudden vision loss and requires immediate medical attention, and severe allergic reactions such as swelling, rash, or anaphylaxis. Systemic anticholinergic toxicity, though rare, may present as dry mouth, rapid heart rate, or confusion, especially in vulnerable populations.

Mydriacyl should not be used in individuals with known hypersensitivity to tropicamide or any excipients, in patients with narrow‑angle or uncontrolled glaucoma, and in those who have recently received miotic agents that could counteract its effect. Caution is also advised for infants, young children, and patients with systemic conditions that may be exacerbated by anticholinergic activity.